about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Bio­gen can't es­cape co­pay kick­back law­suits as Hu­mana al­leges 'seed­ing and sweep­ing' scheme

4 years ago
Pharma

DE­VEL­OP­ING News: Ac­celeron ne­go­ti­at­ing $11B buy­out; 11 promis­ing biotech star­tups; Changes ga­lore at No­var­tis; ...

4 years ago
Weekly

As Bay­er, No­var­tis stack up their ra­dio­phar­ma­ceu­ti­cal da­ta at #ES­MO21, a key de­bate takes shape

4 years ago
R&D
In Focus

Con­ti­nu­ity and di­ver­si­ty: Rafaèle Tord­j­man's women-led VC firm tops out first fund at $630M

4 years ago
Financing

Lat­est news: It’s a no on uni­ver­sal boost­ers; Pa­tient death stuns gene ther­a­py field; In­side Tril­li­um’s $2.3B ...

4 years ago
Weekly

Covid-19 roundup: FDA re­veals boost­er ad­comm ques­tion; Eli Lil­ly's an­ti­body cock­tail cleared for pre­ven­tion

4 years ago
Coronavirus

The Ari­ad vets de­vel­op­ing next-gen TKIs are head­ing back to Nas­daq — and Or­biMed stands to reap the most

4 years ago
Financing
R&D

Who needs pri­ma­ry end­points any­way? Aerie touts sil­ver lin­ings from failed PhI­Ib, plots PhI­II in dry eye dis­ease

4 years ago
R&D

Back-to-back piv­otal fail­ures force Ther­a­vance to lay off 270 staffers, prune R&D fo­cus

4 years ago
People
R&D

Surg­ing US de­mand trig­gers new $2.9B pur­chase of Re­gen­eron's Covid-19 an­ti­bod­ies

4 years ago
Coronavirus

Covid-19 roundup: Gilead touts pre­clin­i­cal promise for oral remde­sivir; Roche pre­pares for virus to be­come en­dem­ic

4 years ago
Coronavirus

Covid-19 roundup: Cure­Vac backs out of man­u­fac­tur­ing con­tracts as de­mand dwin­dles; De­spite PhII/III flop, biotech ...

4 years ago
Coronavirus

Se­r­i­al en­tre­pre­neur Gary Glick sells an­oth­er one of his star­tups for $229M — this time to an un­like­ly buy­er

4 years ago
Deals

Biotech's 'found­ing fa­ther' and in­flu­en­tial deal bro­ker Fred Frank dies at 89

4 years ago
People

Sanofi places new $1.9B bet even as its last sours; Sam Wak­sal's new biotech ideas; Cell ther­a­py time for Roche; and ...

4 years ago
Weekly

Ex­clu­sive: Prison and multi­bil­lion dol­lar buy­outs lat­er, Sam Wak­sal is all in on the biotech game, with some big-name ...

4 years ago
People
Startups

As blue­bird plans its big split, rare dis­ease head An­drew Oben­shain re­cruits Iron­wood vet as CFO

4 years ago
People

Sanofi picks up Kad­mon and its trans­plant drug in $1.9B buy­out, giv­ing Sam Wak­sal 2 Big Phar­ma buy­outs un­der his belt

4 years ago
Deals

Food or drug? FDA blasts Flag­ship-backed mi­cro­bio­me play­er’s ‘non-IND’ Covid-19 tri­al

4 years ago
FDA+

Liv­er tu­mors in an­i­mals trig­ger clin­i­cal hold for Bio­Marin gene ther­a­py — high­light­ing a re­cur­ring con­cern

4 years ago
Cell/Gene Tx
FDA+

Abrupt FDA ex­its spark con­cern; Un­pack­ing key con­cepts at gene ther­a­py sum­mit; 20 lu­mi­nar­ies who re­shaped R&D; and ...

4 years ago
Weekly

Sis­ter to Juno's liso-cel, JW's rel­ma-cel lands sec­ond-ever CAR-T ap­proval in Chi­na

4 years ago
China
Cell/Gene Tx

Amid med­dling con­cerns, FDA con­venes ad­comm for Pfiz­er/BioN­Tech boost­er

4 years ago
Coronavirus

Take­da slammed with sur­prise PhI­II fail­ure on 'break­through' blood can­cer drug, im­plod­ing launch plans

4 years ago
R&D
First page Previous page 44454647484950 Next page Last page
A service from the Financial Times